Navigation Links
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
Date:9/3/2007

Ranbaxy will benefit from the 180 day shared exclusivity on the product

PRINCETON, N.J., Aug. 30 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL), announced today that the Company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Galantamine Hydrobromide Tablets, 4mg (base), 8mg (base), and 12mg (base). Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Total annual market sales for Razadyne were $130.0 million (IMS - MAT: June 2007).

"This tentative approval will provide Ranbaxy Pharmaceuticals Inc. (RPI) with an opportunity to market this product and anticipate sharing in the period of 180 days exclusivity that will be beneficial to the Company, as well as to the U.S. healthcare system. We will launch the product upon final approval, which is anticipated on December 14, 2008. At the time of launch, product will be available immediately to all classes of trade," according to Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

* Razadyne(TM) is a registered trademark of Janssen Pharmaceutica Inc.

CONTACTS: Charles M. Caprariello

Vice President, Corporate Communications

Ranbaxy Inc.

(609) 720-5615

Edwige Buteau

RF Binder Partners Inc.

(212) 994-7517

Anuj Baveja

RF Binder Partners Inc.

(212) 994-7552


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. RANBAXY - enters anti-AIDS segment
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Ranbaxy gets US FDA approval for Lisinopril
4. Ranbaxy Labs Entry Into Anti-Acne Market
5. Ranbaxy trying to make inroads in herbal drugs market
6. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
7. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
8. Ranbaxy opens Drug discovery centre in Gurgaon
9. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
10. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
11. SRL Ranbaxy offers quicker bird flu diagnostic test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Liberty University, has officially announced the appointment of Peter A. Bell, DO, MBA, ... Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty from ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions ... so critically important that we all are aware of our options and are ... proud to announce the launch of its newest edition of "Vision and Hearing" ...
(Date:2/24/2017)... ... 2017 , ... With ProGlass Prism users now have the ability to simulate ... over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, ... ProGlass Prism users are given the tools and effects to generate a fractal ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... ITL Limited, ( ASX: ITD ), ... für das zum 31. Dezember 2016 endende Halbjahr ... vorlegen zu können. Eine vollständige Präsentation „Ergebnisse von ... Sie hier . Glanzpunkte ... 2015: 1,04 Millionen USD; +104 %) Gewinn je ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
Breaking Medicine Technology: